Compass therapeutics announces us fda clearance of investigational new drug application for a phase 2 study of ctx-009, a bispecific antibody that simultaneously targets delta-like ligand 4 (dll4) and vascular endothelial growth factor a (vegf-a)

Boston, jan. 20, 2022 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the u.s. food and drug administration (fda) has cleared its ind application for ctx-009, enabling the company to initiate a global phase 2 clinical trial for ctx-009 in patients who have advanced biliary tract cancers (btc) in the united states and south korea. compass plans to include the existing phase 2 in south korea in this global study, allowing it to expand the ongoing study of ctx-009 under this ind. ctx-009 is a bispecific antibody that simultaneously targets delta-like ligand 4 (dll4) and vascular endothelial growth factor a (vegf-a).
CMPX Ratings Summary
CMPX Quant Ranking